8-K: AdaptHealth Reports Q4, FY25 Results; Guides Strong 2026

AdaptHealth Corp. announced its fourth quarter and full-year 2025 financial results, including a net loss, alongside positive operational growth and robust 2026 financial guidance.

Summary

• Full-year 2025 net revenue decreased by 0.5% to $3,244.9 million, while fourth quarter 2025 net revenue decreased by 1.2% to $846.3 million.
• Organic revenue growth was 1.7% for both the full-year and fourth quarter of 2025.
• Full-year 2025 net loss attributable to AdaptHealth Corp. was $70.8 million, compared to a net income of $90.4 million in 2024, including a $128.0 million non-cash goodwill impairment charge.
• Fourth quarter 2025 net loss attributable to AdaptHealth Corp. was $102.8 million, compared to a net income of $50.3 million in 2024, also including the $128.0 million non-cash goodwill impairment charge.
• Full-year 2025 Adjusted EBITDA decreased by 10.5% to $616.7 million, and fourth quarter 2025 Adjusted EBITDA decreased by 18.7% to $163.1 million.
• Full-year 2025 cash flow from operations increased to $601.8 million from $541.8 million in 2024, while free cash flow decreased to $219.4 million from $235.8 million in 2024.
• Fourth quarter 2025 cash flow from operations increased to $183.2 million from $150.4 million in 2024, and free cash flow increased to $79.3 million from $73.1 million in 2024.
• The company reduced debt by $25 million in Q4 2025, bringing the full-year 2025 debt reduction to $250 million.
• Set patient census records for Sleep Health, Respiratory Health, and Wellness at Home, and a patient retention record for Diabetes Health.
• Acquired a leading HME provider in Hawaii, expanding geographic footprint to 48 states and establishing operations to support a new key capitated contract.
• Made significant investments in critical infrastructure and nearly 500 dedicated employees to secure the first start dates of the new key capitated agreement.
• Advanced digital patient engagement and expanded self-service capabilities, more than doubling myApp users to 327,300 from the fourth quarter of 2024.
• Received credit upgrades from S&P and Moody's rating agencies.
• Provided financial guidance for fiscal year 2026, projecting net revenue of $3.44 billion to $3.51 billion, Adjusted EBITDA of $680 million to $730 million, and free cash flow of $175 million to $225 million.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a mixed report. While operational highlights and 2026 guidance are positive, the significant net losses and Adjusted EBITDA decline in 2025, largely due to a goodwill impairment, temper the overall sentiment.

Positives

• Organic revenue growth of 1.7% for both full-year and fourth quarter 2025.
• Full-year 2025 cash flow from operations increased to $601.8 million from $541.8 million in 2024.
• Fourth quarter 2025 cash flow from operations increased to $183.2 million from $150.4 million in 2024.
• Fourth quarter 2025 free cash flow increased to $79.3 million from $73.1 million in 2024.
• Reduced debt by $25 million in Q4 2025, contributing to a total full-year 2025 debt reduction of $250 million.
• Achieved patient census records for Sleep Health, Respiratory Health, and Wellness at Home.
• Set a patient retention record for Diabetes Health.
• Expanded geographic footprint to 48 states with the acquisition of a leading HME provider in Hawaii.
• Secured the first start dates of a new key capitated agreement, described as the largest in the industry's history.
• Advanced digital patient engagement, more than doubling myApp users to 327,300 from Q4 2024.
• Received credit upgrades from S&P and Moody's rating agencies.
• Provided positive financial guidance for fiscal year 2026, projecting growth in net revenue, Adjusted EBITDA, and free cash flow.

Negatives

• Full-year 2025 net revenue decreased by 0.5% to $3,244.9 million compared to 2024.
• Fourth quarter 2025 net revenue decreased by 1.2% to $846.3 million compared to 2024.
• Full-year 2025 resulted in a net loss attributable to AdaptHealth Corp. of $70.8 million, a significant decline from net income of $90.4 million in 2024.
• Fourth quarter 2025 resulted in a net loss attributable to AdaptHealth Corp. of $102.8 million, a significant decline from net income of $50.3 million in 2024.
• A non-cash goodwill impairment charge of $128.0 million was recorded in both full-year and fourth quarter 2025, significantly impacting net income.
• Full-year 2025 Adjusted EBITDA decreased by 10.5% to $616.7 million compared to 2024.
• Fourth quarter 2025 Adjusted EBITDA decreased by 18.7% to $163.1 million compared to 2024.
• Full-year 2025 free cash flow decreased to $219.4 million from $235.8 million in 2024.
• Fourth quarter 2025 Adjusted EBITDA was impacted by a $14.5 million legal settlement expense and over $10 million in strategic investments to accelerate onboarding the new capitated contract.

Risks

• The outcome of judicial and administrative proceedings to which the company may become a party or governmental investigations could interrupt or limit operations, result in adverse judgments, settlements or fines, and create negative publicity.
• Changes in customer preferences, prospects, and the competitive conditions prevailing in the healthcare sector could materially affect the company's results.
• There may be additional risks that the company presently knows or currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements.

Future Outlook

AdaptHealth Corp. provided financial guidance for fiscal year 2026, projecting net revenue between $3.44 billion and $3.51 billion, Adjusted EBITDA between $680 million and $730 million, and free cash flow between $175 million and $225 million. Management believes the underlying earnings power of the business remains intact despite Q4 2025 impacts, positioning the company for strong financial performance in 2026 and beyond.

Management Comments

• "2025 was a tremendous year of transition in which we made significant strides toward building a stronger operational and financial foundation."
• "We transformed our operating model to position the company for sustained growth."
• "We closed the largest capitated contract in the industry's history."
• "We strengthened our balance sheet by paying down debt while generating cash flow that exceeded expectations."
• "In the fourth quarter, we continued that momentum with strong patient growth across our portfolio, setting new census records in Sleep Health, Respiratory Health, and Wellness at Home."
• "This progress positions us well for strong financial performance in 2026 and beyond."

Industry Context

StockSavvy.ai notes that AdaptHealth's focus on patient-centered, healthcare-at-home solutions aligns with broader industry trends towards decentralized care and digital health engagement. The acquisition in Hawaii and securing a large capitated contract demonstrate strategic expansion and adaptation to evolving payer models, positioning the company to capitalize on the growing demand for home medical equipment and services amidst an aging population and increasing chronic disease prevalence.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global industry benchmarks. Therefore, a direct comparison to industry standards is not possible based solely on the provided information.

Legal Proceedings

• The company may become a party to judicial and administrative proceedings or governmental investigations, which could interrupt or limit operations, result in adverse judgments, settlements, or fines, and create negative publicity.
• A litigation settlement expense of $1.0 million was recorded in Q4 and FY 2025, representing the estimated amount expected to be funded by the Company relating to a previously disclosed securities settlement.
• The 2024 period included a $2.4 million charge for the change in fair value of shares issued in July 2024 following court approval of a securities settlement, and a $0.9 million expense to settle a shareholder derivative complaint.
• The 2025 period included $1.6 million of expenses associated with securities litigation as part of other non-recurring expenses.

Stakeholder Impact

• Shareholders: Experienced a net loss for the year and quarter, but potential for future growth is indicated by 2026 guidance and strategic initiatives. Debt reduction and credit upgrades are positive for financial stability.
• Patients: Benefit from expanded geographic reach (Hawaii), record patient census in key health segments, and enhanced digital engagement through myApp.
• Employees: Significant investments in nearly 500 dedicated employees for the new capitated agreement indicate job growth and stability in certain areas.
• Creditors: Benefit from $250 million in debt reduction for FY 2025 and credit upgrades from S&P and Moody's, indicating improved creditworthiness.
• Customers (Referral Sources): The company's expanded network and strategic contracts may offer broader and more integrated healthcare-at-home solutions.

Next Steps

• Management will host a teleconference on February 24, 2026, at 8:30 am ET to discuss the results and business activities with analysts and investors.
• A replay of the conference call will be available for six months on the company's website, www.adapthealth.com, under Investor Relations.

Key Dates

Recommendation

While AdaptHealth reported a net loss for 2025, primarily due to a significant non-cash goodwill impairment, the underlying operational performance shows organic revenue growth, strong cash flow generation, and substantial debt reduction. The positive 2026 guidance, driven by strategic investments and a major new capitated contract, suggests a potential turnaround. However, the current net losses and Adjusted EBITDA decline warrant a cautious approach. Investors should hold to observe the execution of the 2026 guidance and the realization of benefits from the strategic initiatives before making further investment decisions.

Keywords

AdaptHealth, AHCO, Financial Results, Q4 2025, Full Year 2025, 2026 Guidance, Home Medical Equipment, HME, Sleep Health, Respiratory Health, Diabetes Health, Wellness at Home, Capitated Contract, Debt Reduction, Adjusted EBITDA, Net Revenue, Free Cash Flow, Goodwill Impairment, Healthcare-at-Home